Two series of 4-aryl-3-methyl-1,2,3,4-tetrahydroquinoline derivatives were efficiently synthesized according to a twostep synthesis and evaluated as potential antifungal agents. The key step was the formation of the corresponding N-benzyltetrahydroquinolines 5 via a three-component cationic imino Diels-Alder cycloaddition. The second step was a catalytic debenzylation to obtain the N-unprotected tetrahydroquinolines 6. The products were isolated and purified by column chromatography. Substances were characterized using nuclear magnetic resonance (NMR) mass spectrometry (MS) and infrared spectroscopy (IR). All compounds were tested in vitro against standardized, clinically important fungi, including yeasts, hialohyphomycetes, and dermatophytes. These studies showed that between the tetrahydroquinoline series tested, compounds 6f and 6g showed antifungal activity, specifically against dermatophytes. The compound 6-methoxy-4-(4-hydroxi-3-methoxyphenyl)-3-methyl-1,2,3,4-tetrahydroquinoline 6g exhibited the best in vitro activity (MIC 32-65 μg/mL). The results indicated that the elimination of benzyl group from the N-benzyltetrahydroquinolines derivatives, as well as the introduction of a hydroxyl group in the 4-aryl substituent caused a significant improvement in the antifungal activity. These results were supplemented by the in silico prediction; most of the tetrahydroquinolines evaluated showed high bioavailability, high drugs score and low potential risk.
Introduction
Fungal infections are a common and serious public health issue that can threaten human life, particularly in immunocompromised patients; they have a remarkable impact on morbidity and mortality worldwide especially in tropical and subtropical developing countries (Mathew & Nath 2009 , Pappas 2011 , Brown et al. 2012 . The majority of fungal infections are caused by opportunistic pathogens, which may be endogenous or acquired from the environment. Candida, Cryptococcus and Aspergillus infections are the most common invasive mycotic diseases that affect humans (Pfaller et al. 2006 , Senet et al. 2012 . However, new fungal pathogens that pose a risk at a global scale have emerged, and their incidence continues to increase (Seebacher et al. 2008 , Galimberti et al. 2012 . Some forms of dermatomycoses produced by fungal microorganisms cause high morbidity; they affect the quality of life of patients with AIDS, patients receiving anticancer chemotherapy, or those undergoing organ transplants (Hsu et al. 2011 , Ramos-e-Silva et al. 2012 . The prevalence of superficial mycotic infections is high; 20% of the world's population has skin mycoses, making superficial mycotic infections one of the most frequent forms of infection (Woodfolk 2005 , Havlickova et al. 2008 . Dermatophytic fungi of the genera Trichophyton, Epidermophyton, and Microsporum produce superficial mycoses. This fungi group specifically infects the keratin tissues of the body, causing superficial infections of the skin, hair, or nails, because of their ability to obtain nutrients from keratinized material (Grappel et al. 1974 , Weitzman & Summerbell 1995 . Significant advances have been made in the development and evaluation of new antifungal agents, especially for superficial mycoses (Kathiravan et al. 2012 , Rotta et al. 2012 . Although imidazole compounds such as clotrimazole and miconazole have proven to be an effective treatment for dermatomycoses (Boucher et al. 2004 , Chai et al. 2011 , these fungal infections are often very difficult to eradicate (Li et al. 1995 , Zacchino et al. 1999 .
The clinical efficacy of current antifungal drugs has been limited because of drug resistance, high toxicity risks, and insufficiencies in their antifungal activity and undesirable side effects (Marr et al. 1997 , Sanglard 2002 ). There is a need to develop new, safe and efficient chemotherapeutic agents with potent antifungal activity. As a result, developing new broadspectrum antifungal agents with less toxicity and a better pharmacokinetic profile is crucial.
Because of their remarkable pharmacological applications, natural and synthetic quinoline compounds and their partially reduced derivatives, tetrahydroquinoline, are heterocycles of great importance in medicinal chemistry (Kouznetsov 2009 , Sridharan et al. 2011 ). These compounds have displayed different biological activities, such as antiplasmodial activity (Jaquemond-Collet et al. 2002) ; they are estrogen receptor modulators (Chen et al. 2007 , Wallace et al. 2013 and are, therefore, considered attractive scaffolds for the development of new antifungal agents. Examples of these molecules include a heterocyclic compound with significant antibiotic properties, called helquinoline 1 (Asolkar et al. 2004) , the antifungal agent (N-tetrahydroquinoline) urea derivative 2, which has displayed an MIC value of 12.5 µg/mL against A. Niger and T. Rubrum, respectively (Zheng et al. 2010) , the 2-(4-pyridinyl)-1,2,3,4-tetrahydroquinoline derivative 3, which is highly active against Aspergillus spp. (MIC = 31.2 µg/ mL) and especially against dermatophytes (MIC = 8 µg/mL). More recently, Gutierrez et al. (2012) reported the 2-(furan-2-yl)-1,2,3,4-tetrahydroquinoline 4, which displayed interesting phytopathogenic fungi bioactivity against Cladosporium cladosporoides with MIC values of 13.75 µg/mL.
In the course of our screening for novel and selective bioactive compounds, we have reported the antiparasitic and antifungal activity of some substituted N-heterocycles, including some (tetrahydro)quinolines (Vargas et al. 2003 , Romero et al. 2012 , Fonseca et al. 2013 ). Considering our previous reports and continuing with our program in search of new antifungal agents, we decided to prepare different polyfuntionalized 1,2,3,4-tetrahydroquinolines and test their biological properties. Here, we report the synthesis and in vitro antifungal activity of several 4-aryl-3-methyl tetrahydroquinoline derivatives (5a-h) and (6a-h) against standardized, as well as clinically important fungi including Cryptococcus neoformans, several species of Candida and Aspergillus genus, and dermatophytes. These THQ compounds were prepared using a three-component cationic imino Diels-Alder cycloaddition methodology and a catalytic reduction (Romero & Kouznetsov 2010 ) that provided the N-benzyl-or N-H-1,2,3,4-tetrahydroquinoline derivatives with high structural diversity.
Materials & methods

In silico pharmacological properties study
The preliminary molecular design for 4-aryl-3-methyl-1,2,3,4-tetrahydroquinoline compounds series 5 and 6 was achieved based on structure-activity relationship studies and virtual screening analyses reported in the literature. Five physicochemical parameters of Lipinski's rules were calculated using the Molinspiration virtual platform (http://www.molinspira tion.com/ services/). The profile and toxicity risk assessment was accomplished using the OSIRIS program (http:// www.organic-chemistry.org/prog/peo). The OSIRIS and Molinspiration Property Explorers, shown in these web-pages, are an integral part of some pharmaceutical companies' in-house substance registration system. They allow drawing chemical structures and calculates on-the-fly various drug-relevant properties whenever a structure is valid.
Chemistry
The melting points (uncorrected) were determined using a Fisher-Johns melting point apparatus. We recorded IR spectra on a Lumex Infralum FT-02 spectrophotometer in KBr. C NMR), using CDCl 3 as solvent. TMS was used as an internal standard. J values are reported in Hz; chemical shifts are reported in ppm (δ) relative to the solvent peak (CHCl 3 in CDCl 3 at 7.26 ppm for protons). Signals were designated as follows: s, singlet; d, doublet; dd, doublet of doublets; ddd, doublet of doublets of doublets; t, triplet; td, triplet of doublets; q, quartet; m, multiplet; br., broad. A Hewlett Packard 5890a Series II Gas Chromatograph interfaced to an HP 5972 Mass Selective Detector with an HP MS ChemStation Data system was used for MS identification at 70 eV using a 60 m capillary column coated with HP-5 [5% phenylpoly(dimethylsiloxane)]. We performed elemental analyses on a Perkin-Elmer 2400 Series II analyzer, which were within ±0.4 of theoretical values. The reaction progress was monitored using thin layer chromatography on Silufol UV 254 TLC aluminum sheets. Column chromatography was carried out using Silica gel (60-120 mesh). All reagents were purchased from Sigma and Aldrich Chemical Co. and used without further purification.
General Procedure for the synthesis of N-Benzyl-4-aryl-3-methyltetrahydroquinoline derivatives
The general procedure was previously described by Romero & Kouznetsov (2010) and performed as follows: A mixture of N-benzylaniline (1 mmol) and formaldehyde (37% in MeOH, 1.1 mmol) in MeCN (10 mL) was stirred at r.t. for 10 min. The system was cooled to 0 °C and BF 3 . OEt 2 (1.1 mmol) was added dropwise into the mixture. After 30 min, dienophile reagent (trans-anethole or trans-isoeugenol; 1.1 mmol) was added to the reaction mixture over 5 min. We stirred the resulting mixture at 70 °C for 8 h. After completion of the reaction as indicated by TLC, the reaction mixture was extracted with EtOAc (3 × 15 mL). The organic layer was separated and dried (Na 2 SO 4 ), then, concentrated in vacuo and the crude product was purified by column chromatography using silica gel (60-120 mesh; petroleum ether-EtOAc) to afford pure tetrahydroquinoline 5a-h. 9, 143.2, 139.2, 137.9, 131.0, 129.9 (2C), 128.5 (2C), 127.8, 126.7 (2C), 126.6, 125.0, 124.5, 113.6 (2C), 111.0, 55.6, 55.2, 54.5, 50.7, 34.8, 20.3, 18. 146.5, 143.9, 143.2, 139.2, 137.6, 130.9, 128.5 (2C), 127.8, 126.7, 126.7 (2C), 125.1, 124.5, 122.2, 114.0, 111.1, 110.9, 55.9, 55.6, 54.7, 51.3, 34.7, 20.2, 18 .3. Anal. Calcd for C 25 H 27 NO 2 (373 g/mol): C, 80.40; H, 7.29; N, 3.75. Found: C, 80.58; H, 7.10; N, 3.65 .
General procedure synthesis of N-H-4-Aryl-3-methyltetrahydroquinoline derivatives
The general procedure also was previously described by Romero & Kouznetsov (2010) and performed as follows: A mixture of tetrahydroquinoline 5a-h (1 mmol), wet 10 % Pd/C (cat.) and MeOH-CH 2 Cl 2 (3:1, 20 mL) was stirred under H 2 (1atm) at r.t. for 14-16 h. The reaction mixture was filtered, and the filtrate was concentrated in vacuo and extracted with CH 2 Cl 2 (3 × 15 mL). The organic layer was separated and dried (Na 2 SO 4 ), and concentrated again in vacuo. We purified the resulting product by flash column chromatography (silica gel; petroleum ether-EtOAc) to provide the pure tetrahydroquinoline 6a-h. C-NMR (100 Hz, CDCl 3 Me 4 Si), δ (ppm), presents the following data: 146. 5, 144.0, 142.2, 137.6, 130.9, 127.5, 126.4, 124.4, 122.3, 114.2, 113.9, 111.1, 55.9, 51.1, 47.5, 35.3, 20.4, 18.0 
Biology
Microorganisms and media
Antifungal susceptibility testing
The minimum inhibitory concentration (MIC) of each compound was determined by using broth microdilution techniques according to the guidelines of the National Committee for Clinical Laboratory Standards for yeasts (M27-A3)(CLSI 2008 a) and filamentous fungi (M 38-A2) (CLSI 2008 b) . MIC values were determined in RPMI-1640 (Sigma, St. Louis, Mo, USA) buffered to pH 7.0 with MOPS. Microtiter trays were incubated at 30 ºC for yeasts and species of Aspergillus and 28-30 ºC for dermatophytes in a moist, dark chamber. MICs were visually recorded at 48 h for yeasts, and at intervals according to control fungus growth for the rest of fungi.
For the assay, stock solutions of pure compounds were twofold diluted with RPMI from 250-0.98 µg/mL (final volume = 100 µl) and a final DMSO concentration ≤ 1%. A volume of 100 µl of an inoculum suspension was added to each well with the exception of the sterility control (sterile water was added instead). We used ketoconazole (Sigma Chem. Co.) and terbinafine (Novartis, Bs. As.) as positive controls. Endpoints recorded in Table 4 were defined as the lowest concentration of drug resulting in total inhibition (MIC 100 ) of visual growth compared to the growth in the control wells containing no antifungal. We conducted all tests in duplicate and considered compounds with MICs >250 µg/mL as inactive.
Results
In silico chemoinformatics tools
The pre-screening for hit identification from synthetic compounds libraries was based on the oral bioavailability using Lipinski's rules concepts (Lipinski et al. 1997 ) through the analysis of the rule of five, employing Molinspiration free software ( Table 1) .
We calculated the principal molecular properties, including the number of hydrogen donors (nNHOH), number of hydrogen acceptors (nNO), number of rotatable bonds (nRB) and molecular weight (MW), as well as, another recognized parameter for membrane permeation, prerequisite for bioavailability, the topological polar surface area (TPSA) ( Table 1 ). Other molecular properties tested for the potential risk assessment and associated to some fragments of the synthesized tetrahydroquinoline compounds were evaluated employing Osiris software ( Table 2 ).
The data from this topological analysis allowed us to obtain information on fragments with possible mutagenic (Mut.), tumorigenic (Tum.), irritant (Irr.) and effective reproductive (Eff. Rep.) effects. Prediction results were valued, and color-coded. Properties with medium risks of undesired effects like a mutagenicity or poor intestinal absorption are shown in light orange while green indicates that the substance evaluated has a drug-like behavior. Final molecular properties calculated in this work were the drug-score and the drug-likeness ( Table 2 ). The molecular fragments with frequent occurrence in trade drugs yield positive druglikeness values.
Chemistry
Two series of 4-aryl-3-methyl-1,2,3,4-tetrahydroquinolines derivatives were easily and efficiently synthesized according to a two-step synthesis. The first and key step was the formation of the corresponding N-benzyltetrahydroquinolines 5 via a "one pot" three-component cationic imino Diels-Alder cycloaddition from readily available N-benzylanilines, inexpensive formalin (37% formaldehyde in methanol), and a commercially available trans-anethole (and isoeugenol) in the presence of BF 3 . OEt 2 at 70 ºC in acetonitrile, according to the literature procedure (Romero & Kouznetsov 2010) . The second step was their catalytic debenzylation using hydrogen gas and Pd/C as catalyst to obtain the respective N-unprotected tetrahydroquinolines 6 (Figure 1 ).
Both series of compounds were obtained in good yields after column chromatography purification on silica gel ( Table 3) . The stereochemistry of all these tetrahydroquinoline compounds synthesized (5,6) were determined by IR and MS and confirmed by 1 H and 13 C NMR spectroscopy and supported by inversedetected 2D NMR experiments (COSY, HSQC and HMBC spectra).
Antifungal assays
The in vitro antifungal activity of the 4-aryl-3-methyl-1,2,3,4-tetrahydroquinolines series 5a-h and 6a-h was evaluated against standardized clinically important fungi, including yeasts, hialohyphomycetes, and dermatophytes ( 250 µg/mL were incorporated to growth media according to CLSI standardized procedures (CLSI 2008 a,b) . Terbinafine (Terb) and ketoconazole (Ket) were used as positive controls under the same assay conditions. Table 4 summarizes the minimum concentration of compounds that completely inhibited the growth (MIC100) obtained by nine opportunistic pathogenic fungi including yeasts (Candida albicans, C. neoformans, Saccharomyces cerevisiae), hialohyphomycetes (Aspergillus spp.) as well as dermatophytes (Microsporum and Trichophyton spp.). Table 4 shows the structure of each tetrahydroquinoline derivative to facilitate the analysis of the results.
Discussion
The recognizable need to combat diseases caused by pathogenic fungi has brought about significant advancement in the development and implementation of strategies to obtain new and more potent antifungal agents. In this regard, the pursuit of effective and safer drug against pathogens fungi is an urgent priority. With the preceding in mind and considering that the tetrahydroquinoline ring is a key structural scaffold in many bioactive heterocyclic compounds, including some antifungal agents; here, we report the synthesis, characterization and results of the antifungal assays of the two series of 3-methyl-4-aryl-1,2,3,4-tetrahydroquinolines 5a-h and 6a-h. Figure 2 illustrates the overall synthesis route of the N-benzyl-3-methyl-4-aryl-1,2,3,4-tetrahydroquinoline derivatives 5 and its debenzylated analogous THQs 6; this includes the cycloaddition reaction used as a key-step based on the BF 3 . OEt 2 -catalyzed multicomponent cationic imino DielsAlder reaction among substituted N-benzylanilines, formalin (37 % formaldehyde in methanol), and propenylbenzenes (trans-anethole and isoeugenol) at 70 ºC in CH 3 CN for 6-8 hours. The catalytic debenzylation (10mol% Pd/C) using hydrogen gas (H 2 ) at room temperature over night yielded the corresponding 3-methyl-4-aryl-1,2,3,4-tetrahydroquinoline derivatives 6. Both series of tetrahydroquinolines were largely obtained as stable solid substances with defined melting points and 49-77 % (5a-h) and 93-98 % (6a-h) yields after their chromatography purification ( Table 3 ). All the studied tetrahydroquinolines were isolated and purified by column chromatography (on silica gel) using petroleum ether/ethyl acetate mixtures with gradients of polarity. We confirmed the stereochemistry of all THQ compounds using 1D and 2D NMR experiments. 1 H NMR analysis indicated that the structure of the distinctive diastereoisomers obtained for 5 and 6 were trans-configured with respect to the 3-CH 3 /4-Ar substituents (Figure 2 ).
In silico chemoinformatics tools
The most significant theoretical pharmacokinetic parameters for all tetrahydroquinoline derivatives synthesized (5a-h and 6a-h) in this work were obtained using chemoinformatics platforms. Molinspiration software was used to obtain five properties associated with the Lipinski' rules (Lipinski et al. 1997 ) that indicate whether a chemical can be orally active in humans (drug-likeness). TPSA parameters (Chohan et al. 2010) proved to be a very good descriptor to characterize drug absorption, including intestinal absorption and bioavailability and blood-brain barrier penetration. We found that tetrahydroquinoline derivatives 5a-h violate no more than one of Lipinski' rules while the debenzylated derivatives 6a-h meets the five criteria. All the analyzed tetrahydroquinoline compounds showed high bioavailability properties, similar and comparable with the structures of reference drugs (ketoconazole and terbinafine), largely fulfilling all the parameters set by this rule (molecular weight = 253.34-393.91, log P = 3.26-6.27, nON = 2-4 and nOHNH = 0-2). Prediction results by TPSA parameters for the compounds 5a-h and 6a-h (Table  1) showed TPSA values between 12.5 and 50.7 Å 2 , confirming that this pharmacokinetic parameter is a relevant property in drug design. It should be noted that TPSA values less than 60 Å 2 are defined for compounds with good membrane permeability, as well as penetration of the blood-brain barrier.
In order to assess the possible pharmacological properties and predict the compounds drug-score of the tetrahydroquinolines 5a-h and 6a-h, a toxicity profile evaluation was performed employing the OSIRIS software. Exploring virtually the potential risk associated to different fragments of the synthesized tetrahydroquinoline compounds, it can be noted that -benzyl-4-aryl-3-methyl -1,2,3,4-tetrahydroquinoline (5) and N-H-4-aryl-3-methyl -1,2,3,4-tetrahydroquinoline derivatives (6) >250  >250  >250  >250  >250  250  250  250   5d  >250  >250  >250  >250  >250  >250  >250  >250  >250   5e  >250  >250  >250  >250  >250  >250  >250  >250  >250   5f  >250  >250  >250  >250  >250  >250  250  250  250   5g  >250  >250  >250  >250  >250  >250  250  250  250   5h  >250  >250  >250  >250  >250  >250  >250  >250  >250   6a  >250  >250  >250  >250  >250  >250  >250  >250  >250   6b  >250  >250  >250  >250  >250  >250  >250  >250  >250   6c  >250  >250  >250  >250  >250  >250  125  125  125   6d  >250  >250  >250  >250  >250  >250  >250  >250  >250   6e  >250  >250  >250  >250  >250  >250  >250  >250  >250   6f  >250  >250  >250  >250  >250  >250  31, all obtained and evaluated products presented low biological risks and have few negative effect. The methoxy group in the 6c and 6g compounds on the C-6 position of the tetrahydroquinoline scaffolds showed a moderate mutagenic risk. Nevertheless, the fragments and topology of the reference compound present higher potential risk than all the tetrahydroquinoline molecules evaluated. Performing calculations on drug-likeness and drug-score parameters, we could note that both series afforded favorable numbers, especially for the molecular structures 6a-h. Compared with the antifungal activity of the most active molecules (6f and 6g), the druglikeness calculation showed good correlation and confirmed the importance of removing the benzyl group, and the introduction of a hydroxyl group in the 4-aryl substituent of the tetrahydroquinoline structure (Table 3) . Furthermore, the drug-score obtained for each analyzed molecule showed an important relationship with the in vitro antifungal evaluation for tetrahydroquinolines 6f and 6g, whose values were above the average of all calculated compounds.
Antifungal assays
All compounds were tested in vitro against standardized clinically important fungi, including yeasts, hialohyphomycetes, and dermatophytes. Table  3 presents the results for antifungal activities of all the title compounds; ketoconazole and terbinafine were used as the controls. The table also shows the structure of each tetrahydroquinoline derivative to facilitate the analysis of the results. Between the two tetrahydroquinoline series tested, the results showed that N-H-tetrahydroquinoline derivatives 6a-h have moderate inhibition activities while the N-benzyltetrahydroquinoline series 5a-h showed no antifungal activity (their MIC exceeded 250 μg/mL).
Compounds 6c, 6f and 6g showed particular antifungal activity against the dermatophyte strains assayed. The 6-methoxy-4-(4-hydroxy-3-methoxyphenyl)-3-methyl-1,2,3,4-tetrahydroquinoline 6g exhibit the best in vitro antifungal activity, especially against dermatophytes, including Microsporum gypseum (MIC 31.25 μg/mL), Trichophyton rubrum (MIC 62.5 μg/ mL) and Trichophyton mentagrophytes (MIC 62.5 μg/mL).
Seeking structural parameters that might enhance antifungal activity, we introduced chlorine, methoxy, and methyl substituents onto the 2,4-diaryl 1,2,3,4-tetrahydroquinoline ring; we also used two different dienophiles for the cycloaddition reaction (anethole and isoeugenol) and performed N-debenzylation of the tetrahydroquinoline derivatives 5a-h. Antifungal results indicated that the presence of the methoxy group in compounds 6 showed noteworthy performance; this compound presented bioactivity in comparison to all the other tetrahydroquinoline derivatives tested. Furthermore, inhibition activity results indicated that the elimination of a benzyl group and introduction of a hydroxyl group on 4-aryl substituent of the N-benzyltetrahydroquinolines derivatives 5a-h generated a significant improvement of the antifungal activity of this series (Table 3) .
Conclusion
An easy and efficient synthetic route was employed to prepare two series of 4-aryl-3-methyl-1,2,3,4-tetrahydroquinoline derivatives. The key step involved a three-component cationic imino DielsAlder reaction. This study showed that between the tetrahydroquinolines (THQ) series tested, compounds 6f and 6g showed antifungal activity, specifically against dermatophytes (MIC ≤ 62.5 μg/ mL). The compound 6-methoxy-4-(4-hydroxy-3-methoxyphenyl)-3-methyl-1,2,3,4-tetrahydroquinoline 6g exhibited the best in vitro activity (MIC 32-65 μg/mL). Results indicated that the elimination of a benzyl group from the N-benzyltetrahydroquinolines derivatives and the introduction of a hydroxyl group in the 4-aryl substituent produced a significant improvement in antifungal activity. These results were complemented by an in silico prediction, which revealed the high bioavailability, high drugs score and low potential risk of most of thevtetrahydroquinolines evaluated. We are currently pursuing more complete structure-activity relationship studies to increase in vitro antifungal activity.
